/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Flot.bio x Philip Hemme
  2. Red Hot Rare Diseases and Europe’s record funding with Regina Hodits, Angelini Ventures | E63
Red Hot Rare Diseases and Europe’s record funding with Regina Hodits, Angelini Ventures | E63

Red Hot Rare Diseases and Europe’s record funding with Regina Hodits, Angelini Ventures | E63

Flot.bio x Philip Hemme · Oct 13, 2026

Regina Hodits shares how Angelini Ventures targets rare diseases and why Europe must expand institutional capital across VC stages.

Series A and B Biotech Investors Must Abandon "Spray and Pray" Diversification

Early company creation can rely on small bets across many projects searching for a rare outlier like Moderna. In Series A and B rounds, ticket sizes are too large for spray-and-pray tactics, forcing investors to fund companies toward clear milestones within 18 to 24 months.

Red Hot Rare Diseases and Europe’s record funding with Regina Hodits, Angelini Ventures | E63 thumbnail

Red Hot Rare Diseases and Europe’s record funding with Regina Hodits, Angelini Ventures | E63

Flot.bio x Philip Hemme·a month ago

European Mega-Funds Inadvertently Complicate Capital Raising for Smaller Life Sciences Funds

While multi-billion-euro funds are vital for later-stage European life sciences, their dominance absorbs available institutional capital and strains smaller fund raising. Sustaining a healthy innovation ecosystem requires democratizing institutional allocations rather than directing all capital to mega-funds.

Red Hot Rare Diseases and Europe’s record funding with Regina Hodits, Angelini Ventures | E63 thumbnail

Red Hot Rare Diseases and Europe’s record funding with Regina Hodits, Angelini Ventures | E63

Flot.bio x Philip Hemme·a month ago

Biotech Investors Favor Tangible Lead Assets Over Abstract Technology Platforms

Investors with clinical development heritage struggle to underwrite pure platforms without visible therapeutic applications. Even prominent platform successes ultimately depended on substantial capital deployment into specific lead pipeline assets to reach major commercial inflection points.

Red Hot Rare Diseases and Europe’s record funding with Regina Hodits, Angelini Ventures | E63 thumbnail

Red Hot Rare Diseases and Europe’s record funding with Regina Hodits, Angelini Ventures | E63

Flot.bio x Philip Hemme·a month ago

Top Biotech VCs Protect Fund Returns by Cutting Off Struggling Portfolio Companies

High-performing venture funds execute strict portfolio triage, refusing follow-on funding to underperforming companies regardless of past participation. Evenly distributing capital across all portfolio assets starves top-tier winners of the resources required to achieve critical clinical milestones.

Red Hot Rare Diseases and Europe’s record funding with Regina Hodits, Angelini Ventures | E63 thumbnail

Red Hot Rare Diseases and Europe’s record funding with Regina Hodits, Angelini Ventures | E63

Flot.bio x Philip Hemme·a month ago

Adding Public Institutional LPs Insulates Corporate Venture Funds from Strategic Conflicts

Integrating institutional co-investors like the European Investment Bank imposes formal governance on corporate venture entities. Serving public and private partners enforces strict information boundaries, preventing corporate contamination while granting early-stage biotechs protection against unfair corporate terms.

Red Hot Rare Diseases and Europe’s record funding with Regina Hodits, Angelini Ventures | E63 thumbnail

Red Hot Rare Diseases and Europe’s record funding with Regina Hodits, Angelini Ventures | E63

Flot.bio x Philip Hemme·a month ago

Biotech Venture Investors Must Cultivate Lifelong Scientific Networks to Offset Asymmetric Information

Because life science venture capital suffers from severe information asymmetry, financial models alone cannot de-risk deals. Junior investors must build enduring relationships with peers across academia and industry to access authentic, specialized domain expertise when evaluating complex scientific data.

Red Hot Rare Diseases and Europe’s record funding with Regina Hodits, Angelini Ventures | E63 thumbnail

Red Hot Rare Diseases and Europe’s record funding with Regina Hodits, Angelini Ventures | E63

Flot.bio x Philip Hemme·a month ago